Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Changes in Shareholders' (Deficit) Equity

v3.25.1
Consolidated Statements of Changes in Shareholders' (Deficit) Equity - USD ($)
$ in Thousands
Common Shares
Additional Paid-in Capital
Warrants
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Non-Controlling Interest
Total
Balance at beginning of period at Dec. 31, 2022 $ 858,143 $ 225,127 $ 796 $ 988 $ (963,703) $ 166 $ 121,517
Balance at beginning of period (in shares) at Dec. 31, 2022 377,515,391            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Share-based compensation   56         56
Warrants expired   67 (67)        
Issuance and vesting (forfeiture) of restricted share units $ (487)           (487)
Issuance and vesting (forfeiture) of restricted share units (in shares) 7,318,155            
Shares reserved for contingent consideration $ (1,234)           (1,234)
Warrants issued as part of debt modification     5,106       5,106
CGSF/SFNY Divestiture           1,267 1,267
Comprehensive loss for the period       (15) (62,384) $ (1,433) (63,832)
Balance at end of the period at Dec. 31, 2023 $ 856,422 225,250 5,835 973 (1,026,087)   $ 62,393
Balance at end of period (in shares) at Dec. 31, 2023 384,833,546           384,833,546
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Share-based compensation   263         $ 263
Warrants expired   729 (729)        
Issuance and vesting (forfeiture) of restricted share units $ (179)           (179)
Issuance and vesting (forfeiture) of restricted share units (in shares) 6,397,950            
Comprehensive loss for the period       (9) (99,670)   (99,679)
Balance at end of the period at Dec. 31, 2024 $ 856,243 $ 226,242 $ 5,106 $ 964 $ (1,125,757)   $ (37,202)
Balance at end of period (in shares) at Dec. 31, 2024 391,231,496           391,231,496